<DOC>
	<DOCNO>NCT00650026</DOCNO>
	<brief_summary>Multicenter Early Access Program Safety Human Anti-TNF Monoclonal Antibody Adalimumab Subjects Active Rheumatoid Arthritis</brief_summary>
	<brief_title>Early Access Program Safety Human Anti-TNF Monoclonal Antibody Adalimumab Subjects With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Eighteen year older Females postmenopausal least 1 year , surgically sterile practice acceptable method birth control Females negative pregnancy test screening Confirmed diagnosis active RA &gt; = 6 swollen joint &gt; = 9 tender joint Met ACR criterion diagnosis RA least 3 month Active RA define DAS &gt; = 3.2 study entry Subject prior treatment cyclophosphamide chlorambucil Subjects previously treat total lymphoid irradiation antiCD4 CAMPATH 1H monoclonal antibody result CD4 lymphopenia Prior treatment intravenous immunoglobulin investigational agent 30 day 5 halflives adalimumab Subject history cancer within past 10 year resect basal cell squamous cell carcinoma skin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>